GlaxoSmithKline (LON:GSK) was downgraded by research analysts at Barclays to an “equal weight” rating in a research note issued on Wednesday.
Several other analysts also recently weighed in on GSK. Shore Capital reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 7th. Liberum Capital reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 7th. Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Wednesday, August 15th. Jefferies Financial Group set a GBX 1,775 ($23.19) price objective on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Thursday, August 16th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline in a research note on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 1,512.99 ($19.77).
GlaxoSmithKline stock opened at GBX 1,418 ($18.53) on Wednesday. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($16.14) and a fifty-two week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.